Annual Operating Profit
$394.80 M
+$145.80 M+58.55%
31 December 2023
Summary:
Neurocrine Biosciences annual operaing income is currently $394.80 million, with the most recent change of +$145.80 million (+58.55%) on 31 December 2023. During the last 3 years, it has risen by +$187.00 million (+89.99%). NBIX annual operating profit is now at all-time high.NBIX Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Profit
$184.80 M
+$36.90 M+24.95%
30 September 2024
Summary:
Neurocrine Biosciences quarterly operating income is currently $184.80 million, with the most recent change of +$36.90 million (+24.95%) on 30 September 2024. Over the past year, it has increased by +$34.50 million (+22.95%). NBIX quarterly operating profit is now at all-time high.NBIX Quarterly Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Operating Profit
$588.30 M
+$43.60 M+8.00%
30 September 2024
Summary:
Neurocrine Biosciences TTM operating income is currently $588.30 million, with the most recent change of +$43.60 million (+8.00%) on 30 September 2024. Over the past year, it has increased by +$193.50 million (+49.01%). NBIX TTM operating profit is now at all-time high.NBIX TTM Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBIX Operating Profit Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +22.9% | +49.0% |
| 3 y3 years | +90.0% | +188.8% | +183.1% |
| 5 y5 years | +74.2% | +117.4% | +159.6% |
NBIX Operating Profit High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +90.0% | at high | +5861.3% | at high | +253.8% |
| 5 y | 5 years | at high | +90.0% | at high | +5861.3% | at high | +253.8% |
| alltime | all time | at high | +286.0% | at high | +243.7% | at high | +365.1% |
Neurocrine Biosciences Operating Profit History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $184.80 M(+24.9%) | $588.30 M(+8.0%) |
| June 2024 | - | $147.90 M(+40.5%) | $544.70 M(+15.8%) |
| Mar 2024 | - | $105.30 M(-29.9%) | $470.40 M(+19.1%) |
| Dec 2023 | $394.80 M(+58.6%) | $150.30 M(+6.4%) | $394.80 M(+13.5%) |
| Sept 2023 | - | $141.20 M(+91.8%) | $347.90 M(+18.1%) |
| June 2023 | - | $73.60 M(+147.8%) | $294.50 M(+6.9%) |
| Mar 2023 | - | $29.70 M(-71.3%) | $275.60 M(+10.7%) |
| Dec 2022 | $249.00 M(+19.8%) | $103.40 M(+17.8%) | $249.00 M(+18.8%) |
| Sept 2022 | - | $87.80 M(+60.5%) | $209.60 M(+26.0%) |
| June 2022 | - | $54.70 M(+1664.5%) | $166.30 M(-7.3%) |
| Mar 2022 | - | $3.10 M(-95.2%) | $179.40 M(-13.7%) |
| Dec 2021 | $207.80 M(-36.5%) | $64.00 M(+43.8%) | $207.80 M(-3.6%) |
| Sept 2021 | - | $44.50 M(-34.4%) | $215.60 M(-12.1%) |
| June 2021 | - | $67.80 M(+115.2%) | $245.30 M(-18.3%) |
| Mar 2021 | - | $31.50 M(-56.1%) | $300.10 M(-8.4%) |
| Dec 2020 | $327.50 M(+44.5%) | $71.80 M(-3.2%) | $327.50 M(-3.9%) |
| Sept 2020 | - | $74.20 M(-39.5%) | $340.70 M(-4.5%) |
| June 2020 | - | $122.60 M(+108.1%) | $356.60 M(+30.4%) |
| Mar 2020 | - | $58.90 M(-30.7%) | $273.40 M(+20.7%) |
| Dec 2019 | $226.60 M(+444.7%) | $85.00 M(-5.7%) | $226.60 M(+34.7%) |
| Sept 2019 | - | $90.10 M(+128.7%) | $168.18 M(+27.0%) |
| June 2019 | - | $39.40 M(+225.6%) | $132.40 M(+45.3%) |
| Mar 2019 | - | $12.10 M(-54.5%) | $91.15 M(+119.1%) |
| Dec 2018 | $41.60 M(-141.0%) | $26.58 M(-51.1%) | $41.60 M(-26.8%) |
| Sept 2018 | - | $54.32 M(-3033.2%) | $56.86 M(-1743.3%) |
| June 2018 | - | -$1.85 M(-95.1%) | -$3.46 M(-94.1%) |
| Mar 2018 | - | -$37.45 M(-189.5%) | -$58.88 M(-41.9%) |
| Dec 2017 | -$101.36 M(-31.2%) | $41.83 M(-797.8%) | -$101.36 M(-46.5%) |
| Sept 2017 | - | -$6.00 M(-89.5%) | -$189.45 M(-14.6%) |
| June 2017 | - | -$57.27 M(-28.4%) | -$221.89 M(+7.5%) |
| Mar 2017 | - | -$79.93 M(+72.8%) | -$206.45 M(+40.1%) |
| Dec 2016 | -$147.37 M(+56.4%) | -$46.25 M(+20.3%) | -$147.37 M(+11.8%) |
| Sept 2016 | - | -$38.44 M(-8.1%) | -$131.87 M(+2.0%) |
| June 2016 | - | -$41.83 M(+100.5%) | -$129.28 M(+14.6%) |
| Mar 2016 | - | -$20.86 M(-32.2%) | -$112.77 M(+19.7%) |
| Dec 2015 | -$94.20 M(+46.3%) | -$30.75 M(-14.2%) | -$94.20 M(+12.2%) |
| Sept 2015 | - | -$35.84 M(+41.6%) | -$83.92 M(+29.2%) |
| June 2015 | - | -$25.32 M(+1006.7%) | -$64.94 M(+20.3%) |
| Mar 2015 | - | -$2.29 M(-88.8%) | -$53.97 M(-16.2%) |
| Dec 2014 | -$64.41 M(+29.7%) | -$20.47 M(+21.4%) | -$64.41 M(+16.1%) |
| Sept 2014 | - | -$16.86 M(+17.4%) | -$55.47 M(+9.6%) |
| June 2014 | - | -$14.36 M(+12.9%) | -$50.62 M(+2.4%) |
| Mar 2014 | - | -$12.72 M(+10.4%) | -$49.43 M(-0.5%) |
| Dec 2013 | -$49.68 M(-3530.8%) | -$11.53 M(-4.0%) | -$49.68 M(+68.0%) |
| Sept 2013 | - | -$12.01 M(-8.8%) | -$29.57 M(+37.4%) |
| June 2013 | - | -$13.17 M(+1.5%) | -$21.52 M(+121.1%) |
| Mar 2013 | - | -$12.97 M(-251.2%) | -$9.73 M(-772.3%) |
| Dec 2012 | $1.45 M(-95.7%) | $8.58 M(-316.6%) | $1.45 M(-121.7%) |
| Sept 2012 | - | -$3.96 M(+187.1%) | -$6.69 M(-124.1%) |
| June 2012 | - | -$1.38 M(-23.0%) | $27.71 M(-8.2%) |
| Mar 2012 | - | -$1.79 M(-500.9%) | $30.19 M(-11.0%) |
| Dec 2011 | $33.92 M(-347.2%) | $447.00 K(-98.5%) | $33.92 M(+1.7%) |
| Sept 2011 | - | $30.44 M(+2677.4%) | $33.35 M(+520.7%) |
| June 2011 | - | $1.10 M(-43.5%) | $5.37 M(-432.8%) |
| Mar 2011 | - | $1.94 M(-1603.1%) | -$1.61 M(-88.2%) |
| Dec 2010 | -$13.72 M | -$129.00 K(-105.2%) | -$13.72 M(-47.0%) |
| Sept 2010 | - | $2.47 M(-141.9%) | -$25.87 M(-31.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2010 | - | -$5.89 M(-42.1%) | -$37.97 M(-19.2%) |
| Mar 2010 | - | -$10.17 M(-17.2%) | -$46.99 M(-8.1%) |
| Dec 2009 | -$51.11 M(-40.0%) | -$12.28 M(+27.5%) | -$51.11 M(-24.3%) |
| Sept 2009 | - | -$9.63 M(-35.4%) | -$67.50 M(-8.3%) |
| June 2009 | - | -$14.90 M(+4.2%) | -$73.57 M(-6.6%) |
| Mar 2009 | - | -$14.30 M(-50.1%) | -$78.78 M(-7.6%) |
| Dec 2008 | -$85.25 M(-59.8%) | -$28.66 M(+82.5%) | -$85.25 M(-54.0%) |
| Sept 2008 | - | -$15.70 M(-21.9%) | -$185.18 M(-6.6%) |
| June 2008 | - | -$20.12 M(-3.1%) | -$198.30 M(-3.6%) |
| Mar 2008 | - | -$20.76 M(-83.9%) | -$205.73 M(-3.1%) |
| Dec 2007 | -$212.24 M(+87.3%) | -$128.59 M(+346.1%) | -$212.24 M(+112.4%) |
| Sept 2007 | - | -$28.83 M(+4.6%) | -$99.91 M(-10.2%) |
| June 2007 | - | -$27.55 M(+1.0%) | -$111.28 M(-1.5%) |
| Mar 2007 | - | -$27.27 M(+67.7%) | -$113.00 M(-0.3%) |
| Dec 2006 | -$113.32 M(+352.0%) | -$16.26 M(-59.5%) | -$113.32 M(-6.8%) |
| Sept 2006 | - | -$40.20 M(+37.4%) | -$121.65 M(+116.0%) |
| June 2006 | - | -$29.26 M(+6.1%) | -$56.33 M(+69.1%) |
| Mar 2006 | - | -$27.59 M(+12.2%) | -$33.32 M(+32.9%) |
| Dec 2005 | -$25.07 M(-52.1%) | -$24.59 M(-197.9%) | -$25.07 M(+15.7%) |
| Sept 2005 | - | $25.12 M(-501.8%) | -$21.66 M(-56.5%) |
| June 2005 | - | -$6.25 M(-67.7%) | -$49.81 M(-12.5%) |
| Mar 2005 | - | -$19.35 M(-8.7%) | -$56.95 M(+8.8%) |
| Dec 2004 | -$52.33 M(-11.0%) | -$21.18 M(+598.9%) | -$52.33 M(+7.9%) |
| Sept 2004 | - | -$3.03 M(-77.4%) | -$48.52 M(-17.9%) |
| June 2004 | - | -$13.39 M(-9.1%) | -$59.06 M(+1.5%) |
| Mar 2004 | - | -$14.73 M(-15.2%) | -$58.16 M(-1.1%) |
| Dec 2003 | -$58.79 M(-43.3%) | -$17.37 M(+28.0%) | -$58.79 M(-28.9%) |
| Sept 2003 | - | -$13.57 M(+8.7%) | -$82.69 M(-9.7%) |
| June 2003 | - | -$12.49 M(-18.6%) | -$91.62 M(-9.4%) |
| Mar 2003 | - | -$15.35 M(-62.8%) | -$101.15 M(-2.4%) |
| Dec 2002 | -$103.61 M(+136.1%) | -$41.27 M(+83.4%) | -$103.61 M(+33.3%) |
| Sept 2002 | - | -$22.50 M(+2.2%) | -$77.75 M(+43.8%) |
| June 2002 | - | -$22.02 M(+23.6%) | -$54.05 M(+13.5%) |
| Mar 2002 | - | -$17.82 M(+15.7%) | -$47.62 M(+8.5%) |
| Dec 2001 | -$43.88 M(+23.3%) | -$15.40 M(-1391.2%) | -$43.88 M(+10.3%) |
| Sept 2001 | - | $1.19 M(-107.7%) | -$39.79 M(-21.5%) |
| June 2001 | - | -$15.59 M(+10.7%) | -$50.67 M(+19.3%) |
| Mar 2001 | - | -$14.08 M(+24.5%) | -$42.45 M(+19.2%) |
| Dec 2000 | -$35.60 M(+78.9%) | -$11.31 M(+16.8%) | -$35.60 M(+21.5%) |
| Sept 2000 | - | -$9.69 M(+31.2%) | -$29.29 M(+19.0%) |
| June 2000 | - | -$7.38 M(+2.1%) | -$24.61 M(+9.3%) |
| Mar 2000 | - | -$7.23 M(+44.5%) | -$22.52 M(+13.8%) |
| Dec 1999 | -$19.90 M(+60.5%) | -$5.00 M(0.0%) | -$19.79 M(+7.0%) |
| Sept 1999 | - | -$5.00 M(-5.5%) | -$18.49 M(+11.5%) |
| June 1999 | - | -$5.29 M(+17.6%) | -$16.59 M(+12.9%) |
| Mar 1999 | - | -$4.50 M(+21.6%) | -$14.70 M(+16.7%) |
| Dec 1998 | -$12.40 M(-2580.0%) | -$3.70 M(+19.4%) | -$12.60 M(+23.5%) |
| Sept 1998 | - | -$3.10 M(-8.8%) | -$10.20 M(+36.0%) |
| June 1998 | - | -$3.40 M(+41.7%) | -$7.50 M(+50.0%) |
| Mar 1998 | - | -$2.40 M(+84.6%) | -$5.00 M(-933.3%) |
| Dec 1997 | $500.00 K(-82.8%) | -$1.30 M(+225.0%) | $600.00 K(-88.5%) |
| Sept 1997 | - | -$400.00 K(-55.6%) | $5.20 M(+26.8%) |
| June 1997 | - | -$900.00 K(-128.1%) | $4.10 M(-34.9%) |
| Mar 1997 | - | $3.20 M(-3.0%) | $6.30 M(+117.2%) |
| Dec 1996 | $2.90 M | $3.30 M(-320.0%) | $2.90 M(-825.0%) |
| Sept 1996 | - | -$1.50 M(-215.4%) | -$400.00 K(-136.4%) |
| June 1996 | - | $1.30 M(-750.0%) | $1.10 M(-650.0%) |
| Mar 1996 | - | -$200.00 K | -$200.00 K |
FAQ
- What is Neurocrine Biosciences annual operaing income?
- What is the all time high annual operating profit for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly operating income?
- What is the all time high quarterly operating profit for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly operating profit year-on-year change?
- What is Neurocrine Biosciences TTM operating income?
- What is the all time high TTM operating profit for Neurocrine Biosciences?
- What is Neurocrine Biosciences TTM operating profit year-on-year change?
What is Neurocrine Biosciences annual operaing income?
The current annual operating profit of NBIX is $394.80 M
What is the all time high annual operating profit for Neurocrine Biosciences?
Neurocrine Biosciences all-time high annual operaing income is $394.80 M
What is Neurocrine Biosciences quarterly operating income?
The current quarterly operating profit of NBIX is $184.80 M
What is the all time high quarterly operating profit for Neurocrine Biosciences?
Neurocrine Biosciences all-time high quarterly operating income is $184.80 M
What is Neurocrine Biosciences quarterly operating profit year-on-year change?
Over the past year, NBIX quarterly operating income has changed by +$34.50 M (+22.95%)
What is Neurocrine Biosciences TTM operating income?
The current TTM operating profit of NBIX is $588.30 M
What is the all time high TTM operating profit for Neurocrine Biosciences?
Neurocrine Biosciences all-time high TTM operating income is $588.30 M
What is Neurocrine Biosciences TTM operating profit year-on-year change?
Over the past year, NBIX TTM operating income has changed by +$193.50 M (+49.01%)